Skip to main content
Premium Trial:

Request an Annual Quote

Illumina and Siemens to Co-Develop MDx Tests on the MiSeq

Premium

Illumina and Siemens Healthcare Diagnostics said today that they will co-develop molecular diagnostic tests on Illumina's MiSeq sequencer.

The companies plan to initially convert Siemens' Trugene HIV genotyping assay, which is currently run on Siemens' Sanger-based OpenGene sequencing system, to the MiSeq.

Eventually, the companies will adapt all of Siemens' HIV tests for the MiSeq, as well as other infectious disease assays.

Additionally, the companies said they aim to "set new standards" in using next-generation sequencing to identify infectious diseases in patients and to guide potential treatments.

Michael Reitermann, CEO of Siemens Healthcare Diagnostics, said in a statement that next-gen sequencing will "significantly impact clinical diagnostics over the next five years," and that the partnership with Illumina would help to "set a new standard of care in the next wave of clinical diagnostics and personalized medicine."

Illumina's CEO Jay Flatley added that partnerships with MDx companies like Siemens are a "key element" of the company's strategy to "drive widespread adoption of the MiSeq in the clinical setting."

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.